Canaccord resumed coverage of Knight Therapeutics with a Buy rating and C$7.25 price target. The firm is resuming research coverage of several Canadian healthcare and wellness companies, calling DRI Healthcare Trust its current top pick among the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
- Knight Therapeutics price target raised to C$7 from C$6.50 at RBC Capital
- Knight Therapeutics Achieves Record Growth
- Knight Therapeutics sees 2024 revenue C$335M-C$350M
